Eli Lilly and Company (LLY)
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are the price of admission to elite returns. No champion in the market rises without scar tissue.
Eli Lilly: It Is A Bet On Human Longevity
Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. Driven by blockbuster drugs Mounjaro and Zepbound, Lilly's revenue surged 45% YoY. Near-term PBM headwinds are manageable, given the drugs' superior clinical data and massive market demand. Beyond current successes, Lilly is innovating with a potential game-changing oral GLP-1 (orforglipron) and a visionary "one-and-done" gene therapy acquisition (Verve) targeting heart disease.
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey Emmick - Vice President of Diabetes Product Development Kenneth L Custer - Executive VP & President of Lilly Cardiometabolic Health Michael Czapar - Director of Investor Relations Ruth Gimeno - Corporate Participant Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Bryan Russell Dollinger - Leerink Partners LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Lilly expects orforglipron obesity results in third quarter
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes.
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug
Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country's state-run health service.
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Even though oncology, the segment in which the acquisition was made, has been lackluster in Q1 2025, it shows promise when seen over the longer term. In any case, there's a case for the company to diversify at a time when it's facing downward pressure on prices from policy, compounders, and fakes.
